http://www.shop4weightloss.com/exuberant-male/

Exuberant MaleTestosterone therapy (TTh) is often used to treat symptomatic hypogonadal men. The use of TTh nearly tripled between 2001 and 2011, rendering therapies for hypogonadism one of the most rapidly growing pharmaceutical product categories[5]. However, following this period of initial growth, T prescriptions significantly declined between 2013 and 2016[6]. Several factors contributed to this decline, including a 2015 Food and Drug Administration (FDA) safety announcement attributing a potentially increased cardiovascular risk to TTh[7]. These concerns were compounded by fears that TTh increases prostate cancer risk. Socioeconomic forces also influenced the downward trend in TTh use. Le et al. noted that reimbursement and insurance coverage for TTh lack transparency and hinder patients from receiving appropriate care for hypogonadism[8]. The authors concluded that regulatory and structural barriers were in part forcing patients to actively employ online marketplaces to research and procure alternatives to prescription testosterone